212 related articles for article (PubMed ID: 36926986)
21. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
[TBL] [Abstract][Full Text] [Related]
22. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
Amatu A; Sartore-Bianchi A; Bencardino K; Pizzutilo EG; Tosi F; Siena S
Ann Oncol; 2019 Nov; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
[TBL] [Abstract][Full Text] [Related]
23. NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma.
Wang Y; Long P; Wang Y; Ma W
Front Oncol; 2020; 10():593578. PubMed ID: 33330081
[TBL] [Abstract][Full Text] [Related]
24. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
[TBL] [Abstract][Full Text] [Related]
25. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
[TBL] [Abstract][Full Text] [Related]
26. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
[TBL] [Abstract][Full Text] [Related]
27. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
28. Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.
Bridgewater J; Jiao X; Parimi M; Flach C; Stratford J; Kamburov A; Schmitz AA; Zong J; Reeves JA; Keating K; Bruno A; Fellous M; Pereira MB; Bazhenova L
Cancer Treat Res Commun; 2022; 33():100623. PubMed ID: 36041373
[TBL] [Abstract][Full Text] [Related]
29. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
30. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
[TBL] [Abstract][Full Text] [Related]
31. Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis.
Lemelle L; Guillemot D; Hermann AL; Gauthier A; Carton M; Corradini N; Rome A; Berlanga P; Jourdain A; Marie Cardine A; Jannier S; Boutroux H; Defachelles AS; Aerts I; Geoerger B; Karanian M; Doz F; Brisse HJ; Schleiermacher G; Delattre O; Pierron G; Orbach D
Expert Rev Anticancer Ther; 2023; 23(8):865-874. PubMed ID: 37434345
[TBL] [Abstract][Full Text] [Related]
32. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
[TBL] [Abstract][Full Text] [Related]
34. NTRK fusions in thyroid cancer: Pathology and clinical aspects.
Ma Y; Zhang Q; Zhang K; Liang Y; Ren F; Zhang J; Kan C; Han F; Sun X
Crit Rev Oncol Hematol; 2023 Apr; 184():103957. PubMed ID: 36907364
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R; Elisei R; Hoff AO; Liu Z; Pitoia F; Pruneri G; Sadow PM; Soares F; Turk A; Williams MD; Wirth LJ; Cabanillas ME
JAMA Oncol; 2023 Aug; 9(8):1132-1141. PubMed ID: 37289450
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.
Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT
Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952
[TBL] [Abstract][Full Text] [Related]
37. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
[No Abstract] [Full Text] [Related]
38. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
Forschner A; Forchhammer S; Bonzheim I
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
[TBL] [Abstract][Full Text] [Related]
39. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.
Xu C; Si L; Wang W; Li Z; Song Z; Wang Q; Liu A; Yu J; Fang W; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Cai X; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Lin R; Liu W; Rao C; Lv D; Yu Z; Lei L; Li X; Tang C; Zhou C; Zhang J; Xue J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Hu X; Zhou J; Zhu Z; Li Y; Qiu H; Xia F; Lu Y; Chen X; Ge R; Dai E; Han Y; Pan W; Luo J; Jia H; Dong X; Pang F; Wang K; Wang L; Zhu Y; Xie Y; Lin X; Cai J; Wei J; Lan F; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Wei Q; Kang J; Zhang J; Zhang C; Yu G; Ou J; Shi L; Li Z; Liu Z; Liu J; Yang N; Wu L; Wang H; Jin G; Yang L; Wang G; Fang M; Fang Y; Li Y; Wang X; Zhang Y; Ma S; Wang B; Zhang X; Song Y; Lu Y
Thorac Cancer; 2022 Nov; 13(21):3084-3097. PubMed ID: 36127731
[TBL] [Abstract][Full Text] [Related]
40. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
